Ekso Bionics Holdings, Inc. (EKSO) Stock Rating Lowered by Zacks Investment Research
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Ekso Bionics Holdings (EKSO) traded down 6.30% during mid-day trading on Wednesday, reaching $1.19. 534,152 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $1.52 and a 200 day moving average price of $2.22. Ekso Bionics Holdings has a 52-week low of $0.99 and a 52-week high of $6.38. The company’s market cap is $30.69 million.
COPYRIGHT VIOLATION WARNING: “Ekso Bionics Holdings, Inc. (EKSO) Stock Rating Lowered by Zacks Investment Research” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/13/ekso-bionics-holdings-inc-ekso-stock-rating-lowered-by-zacks-investment-research.html.
In other news, insider Russ Angold sold 221,746 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $1.55, for a total transaction of $343,706.30. Following the completion of the transaction, the insider now directly owns 400,678 shares of the company’s stock, valued at approximately $621,050.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 259,352 shares of company stock valued at $399,373 over the last ninety days. Company insiders own 7.10% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Intellectus Partners LLC grew its stake in shares of Ekso Bionics Holdings by 5.3% during the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after acquiring an additional 5,294 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Ekso Bionics Holdings by 32.9% during the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after acquiring an additional 176,197 shares in the last quarter. National Planning Corp grew its stake in shares of Ekso Bionics Holdings by 116.2% during the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after acquiring an additional 126,000 shares in the last quarter. Carl Domino Inc grew its stake in shares of Ekso Bionics Holdings by 74.7% during the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after acquiring an additional 35,088 shares in the last quarter. Finally, Independence Advisors LLC bought a new position in shares of Ekso Bionics Holdings during the 2nd quarter worth approximately $1,840,000. 6.04% of the stock is owned by institutional investors.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.